You are here

Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib

Last updated on September 4, 2019

FOR MORE INFORMATION
Study Location
University of Calgary
Calgary, Alberta, P2N4N2 Canada
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Metastatic Renal Cell Carcinoma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Diagnosed with mRCC

- Initiated treatment post mRCC diagnosis and received sunitinib as first-line therapy

- Age 18 years or over at the time of mRCC diagnosis

- Actively treated at an IMDC clinical center

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Initiated first line sunitinib treatment before 2010

- Had non-clear cell mRCC

NCT04076787
Pfizer
Completed
Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now